NCT03349502View on ClinicalTrials.gov

MG4101 for Refractory or Relapsed AML

PHASE2CompletedINTERVENTIONAL
Enrollment

11

Participants

Timeline

Start Date

November 1, 2017

Primary Completion Date

March 30, 2020

Study Completion Date

April 30, 2020

Conditions
Acute Myeloid Leukemia
Interventions
DRUG

MG4101

Administration of study drug (MG4101) for the patients with refractory or relapsed acute myeloid leukemia (Single arm)

Trial Locations (1)

03080

Seoul National University Hospital, Seoul

All Listed Sponsors
lead

Seoul National University Hospital

OTHER

NCT03349502 - MG4101 for Refractory or Relapsed AML | Biotech Hunter | Biotech Hunter